Good morning, welcome to the IDEXX Laboratories second quarter 2023 earnings conference call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer; Brian McKeon, Chief Financial Officer; and John Ravis, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today. Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning, as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the investor relations section of our website, idexx.com. During this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable measures are provided in our earnings release, which may also be found by visiting the investor relations section of our website. In reviewing our second quarter 2023 results, please note all references to growth, organic growth, and comparable growth refer to growth compared to the equivalent period in 2022, unless otherwise noted. To allow broad participation in the Q&A, we ask that each participant limit their questions to one, with one follow-up as necessary. We appreciate you may have additional questions, so please feel free to get back into the queue, and if time permits, we'll take your additional questions. Today's prepared remarks will be posted to the investor relations section of idexx.com after the earnings conference call concludes. I would now like to turn the call over to Brian McKeon. Good morning, welcome to our second quarter earnings call. Today, I'll take you through our Q2 results and review our updated financial outlook for 2023. In terms of highlights, IDEXX achieved strong growth and financial performance in the second quarter, aligned with our full-year performance goals. Overall revenues increased 10% organically, supported by 12% organic growth in CAG Diagnostic recurring revenues, with double-digit gains in US and international regions. The execution metrics remained very strong globally, reflected in record second quarter premium instrument placements, continued solid new business gains, and sustained high growth in recurring veterinary software revenues. Operating profit results were ahead of our expectations, reflecting solid gross margin gains and operating expense leverage, both benefiting from strong CAG recurring revenue growth. For the first half of 2023, we achieved 10% overall organic revenue growth and nearly 12% growth in CAG Diagnostic recurring revenues. We also achieved better than targeted operating margin improvement. We've made positive refinements to our full-year operational outlook incorporating this performance, which we'll discuss later in my comments. Let's begin with a review of our second quarter results. Second quarter organic revenue growth of 10% was driven by 11% CAG gains and 9% organic growth in our water business. Overall organic revenue growth was constrained by modest gains in our LPD business and approximately $3 million of headwind related to lower OPTI Medical revenues, reflecting the wind down of our human COVID testing business. CAG Diagnostic recurring revenue increased 12% organically, reflecting 12% gains in the U.S. and 10% growth in international regions. CAG Diagnostics recurring revenue growth in Q2 was supported by global net price gains at the higher end of our targeted 8%-9% improvement range for the first half of 2023. Overall organic growth, revenue growth was supported by 13% growth in veterinary software and diagnostic imaging revenues. CAG instrument revenues were down 6% organically, reflecting comparisons to high prior year levels, program pricing effects, and global mix. IDEXX CAG Diagnostic recurring revenue growth remained solidly above sector growth levels. In the US, we achieved a consistent, strong 1,370 basis point growth premium in Q2 compared to same-store U.S. clinical visit growth levels, which declined an estimated 1.3% in the quarter. These results reflect benefits from IDEXX execution drivers, including higher net price realization. Solid U.S. volume growth was supported by new business gains, high customer retention levels, and continued increases in diagnostic frequency and utilization at the practice level. International CAG Diagnostic recurring revenues growth improved organically to 10% in Q2, reflecting positive volume gains and benefits from higher net price realization. International results were also supported by strong IDEXX execution, reflected in sustained new business gains and record Q2 premium instrument placements, which supported a double-digit expansion of our premium instrument install base. Double-digit growth rate benefits from IDEXX execution offset impacts from challenging international macro conditions, which continued to pressure same-store volume growth trends in the quarter. Globally, Q2 results were supported by strong growth of IDEXX in-clinic CAG Diagnostic revenues. IDEXX VetLab consumable revenues increased 15% organically, with double-digit gains in U.S. and international regions. Consumable gains were supported by 11% year-on-year growth in our global premium instrument install base, reflecting strong gains across our Catalyst premium hematology and set of new platforms. We placed 4,740 CAG premium instruments in Q2, an increase of 7% year-on-year compared to very strong prior year levels, which included benefits from our international launch of ProCyte One. Catalyst placements increased 15% globally, reflecting 8% gains in the U.S. and 19% placement growth in international regions. The quality of instrument placements continues to be excellent, demonstrated by 9% global growth in new and competitive Catalyst placements and solid gains in EVI metrics. ProCyte One momentum also continues to be strong globally, reflected in a global install base of approximately 10,800 instruments. Global rapid assay revenues expanded 12% organically in Q2, driven by strong growth in the U.S., reflecting solid volume gains and benefits from higher net price realization. Global lab revenues increased 9% organically, reflecting double-digit gains in the U.S. and mid-single-digit growth in international, with growth in international regions moderated by macroeconomic impacts, which pressured same-store sales. In other areas of our CAG business, veterinary software and diagnostic imaging revenues increased 13% organically. Results were supported by continued high levels of organic growth in recurring software and digital imaging revenues, and ongoing momentum in cloud-based software placements. Water revenue increased 9% organically in Q2, reflecting continued solid gains in the U.S., Europe, and Latin America, including benefits from net price improvement. The integration and performance of our recent Tecta-PDS acquisition continues to progress well, expanding our capabilities in water safety testing and adding approximately 2% to reported water growth. Livestock, poultry, and dairy revenue increased 1% organically, as strong gains in the U.S. were offset by impacts from lower herd health screening revenues related to reduced China import testing. Turning to the P&L, Q2 profit results were supported by solid gross profit gains. Gross profit increased 11% in the quarter as reported, and 13% on a comparable basis. Gross margins were 60.7%, up 160 basis points on a comparable basis. These gains reflect benefits from higher net price realization, lab productivity and operational initiatives, improvement in software service gross margins and business mix, which offset inflationary cost effects. As expected, reported gross margin gains were moderated by a 60 basis point negative impact related to foreign exchange changes, including the lapping of prior year hedge gains. While foreign exchange trends have improved, we're expecting approximately 70-80 basis points of negative impact in year-on-year reported gross margin comparisons in the second half of 2023, as we work through lapping of $18 million of prior year foreign exchange hedge gains. On a reported basis, operating expenses decreased 17% year-on-year, reflecting a 26% favorable growth rate impact from comparisons to prior year levels, which included $80 million in discrete R&D investment. Adjusting for this effect, operating expense growth was modestly below revenue growth in the quarter, supporting operating margin gains. EPS was $2.67 per share in Q2, an increase of 71% as reported. On a comparable basis, EPS increased 77%, including approximately 54% of growth rate benefit from lapping the $0.72 per share prior year impact from discrete R&D investments. Foreign exchange reduced operating profits by $8 million and EPS by $0.07 per share in the quarter, including impacts from the lapping of $6 million in prior year hedge gains. Impacts from 2023 foreign exchange hedges were limited in the quarter. Free cash flow was $173 million in the second quarter. On a trailing 12-month basis, our net income to free cash flow conversion ratio was 75%. For the full year, we're maintaining our outlook for free cash flow conversion of 80%-90%, including estimated capital spending of approximately $180 million. Our balance sheet remains in a strong position. We ended the quarter with leverage ratios of 0.9x gross and 0.7x net of cash. Share repurchases over the last year supported a 1% reduction in diluted shares outstanding. We didn't allocate capital to share repurchases in the second quarter, as we managed our balance sheet relatively more conservatively in the current interest rate environment. Turning to our 2023 P&L outlook, we're refining our full-year outlook to incorporate our solid first half operating results and updated estimates for foreign exchange impacts. Our updated full-year guidance for reported revenues is $3.66 billion-$3.715 billion, reflecting an 8.5%-10% organic growth range. This outlook includes a $15 million favorable adjustment for foreign exchange changes, which we now estimate will have a relatively flat full-year impact on reported revenue growth at the rate shown in our press release. In terms of our operational growth outlook, we're maintaining our performance goals aligned with the high end of our guidance range of 10% overall organic revenue growth, supported by 11% CAG Diagnostic recurring revenue gains. This reflects expectations for consistent, strong levels of IDEXX execution aligned with H1 trends. Our outlook incorporates approximately 1% of expected H2 headwinds for CAG Diagnostic recurring revenues from equivalent days effects. Consistent with earlier guidance, our high-end outlook for CAG Diagnostic recurring revenue growth reflects expectations for 6%-7% net price gains and a relative flattening of U.S. same-store clinical visit growth trends in H2. We've raised the low end of our full-year organic revenue growth outlook by 1% to reflect our strong first half performance. We've also made positive adjustments to our outlook for operating margin performance in 2023. Our updated outlook is for reported operating margins in the range of 29.3%-29.7% for the full year. At the high end, this reflects an outlook for approximately 360 basis points in comparable operating margin expansion. This includes approximately 280 basis points in combined benefit from the $16 million Q1 customer contract resolution payment and the lapping of $80 million of discrete R&D investment in the second quarter of 2022. Our operating margin outlook reflects expectations for moderated year-on-year comparable gross margin gains in the second half compared to strong prior year levels. We continue to project that foreign exchange will reduce operating margins by approximately 60 basis points this year, primarily related to impacts from the lapping of $26 million in 2022 hedge gains. We estimate that foreign exchange impacts will decrease EPS by approximately $0.21 per share for the full year, with approximately $0.02 per share of negative impact in the second half, including effects from hedge gain lapping. Our updated EPS outlook is $9.64-$9.90 per share. This is an increase of $0.23 per share at midpoint, reflecting $0.17 in benefit from our raised operational outlook and $0.06 in combined benefit from refined interest expense and foreign exchange estimates. In terms of our operational outlook for Q3, we're planning for organic revenue growth at the lower end of our updated full-year growth range, incorporating expected impacts from approximately 1% of equivalent day headwinds. We expect foreign exchange to provide approximately 1.5% in reported growth rate benefit in the quarter. We're planning for operating margins in the 28.5%-29% range, reflecting expectations for relatively consistent comparable operating margin performance, adjusting for unfavorable foreign exchange margin impacts of approximately 50 basis points, driven by hedge gain lapping. We've provided details on our updated full-year outlook in the press release tables and earnings snapshot. That concludes our financial review. I'll now turn the call over to Jay for his comments. Thank you, Brian, and good morning. IDEXX once again delivered strong results, supported by outstanding execution in the second quarter. We advanced our strategy by engaging customers with integrated testing solutions that support their mission and address real-world clinical and practice problems. Demand for medical services remains high, and veterinarians see diagnostics as a core enabler to guide individualized best care. As a result, we saw strong diagnostic sector revenue growth, with continued gains in diagnostics, testing frequency, and utilization. IDEXX remains well-positioned to further benefit from these trends, thanks to our decades-long focus on diagnostics and the software solutions that deliver key differentiated insights into the patient's health. IDEXX's strong results are reflected in double-digit total company organic revenue growth, supported by expansion of CAG Diagnostic recurring revenues across regions. For the first time ever, U.S. revenues exceeded $1 billion in the first half of 2023. IDEXX execution drivers continued to fire on all cylinders, as reflected in our financial results, including growth in high-quality premium instrument placements, sustained high customer retention levels, contribution from new business gains, and net price realization that remains aligned with our expectations. IDEXX commercial teams delivered yet another record quarter of global premium instrument placements, building off high prior year levels and supporting solid EVI gains for the quarter. IDEXX Diagnostics and software solutions deliver key insights and productivity improvements through workflow transformation. These results demonstrate that greater number of clinicians are partnering with IDEXX, with the aim to deliver higher care standards and crucial efficiency gains. This support continues to be important given persistent clinic productivity constraints in a dynamic macro backdrop. Today, I'll discuss how IDEXX delivered continued strong performance through key strategic initiatives aimed at driving sector development. I'll start by providing an update on our global commercial execution. It's a key component in driving increased testing utilization of both existing customers as well as new to IDEXX accounts. Veterinarians around the world seek testing solutions that provide them with key diagnostic insights necessary to choosing and delivering the right care path in an efficient and intuitive way. IDEXX commercial teams, as trusted advisors, seek to provide the most appropriate solution given a practice's objectives. There's a deep appetite for point-of-care solutions that deliver the right performance, ease of use, workflow integration, and economics. Therefore, it was gratifying to see a record second quarter of global premium instrument placements, with record placements in both the U.S. and internationally. Second quarter premium placements reflected growth across regions and platforms, highlighting the value that clinicians across different geographies at various stages of practice maturity see in our highly innovative platforms and integrated ecosystem. An important dimension of this success is our menu of customer-friendly marketing programs to adopt IDEXX innovations. The result was continued solid gains in EVI and excellent contribution from new business gains, including a new key U.S. corporate account. Very strong ongoing placement performance and our solid relationships with accounts of all types reinforces our confidence in future flow-through of recurring revenues and our ability to address the estimated 220,000 global instrument placement opportunities. Our commercial performance this year demonstrates that we have developed the right suite of innovative products to address this significant opportunity. ProCyte One is a great example of this. It's our newest, easy-to-use, premium hematology platform. ProCyte One boosts efficiency. Gains, including load and go, reagents, and paper run models, while still delivering uncompromised accuracy. It has been a key driver of strong premium hematology placement since its launch in early 2021, and supported record second quarter premium hematology placements. Not only does the growing hematology installed base support flow-through of recurring revenues, but also drives our broader in-clinic business. Sustained mid-90% attach rates with Catalyst provide a multiplier benefit that drives growth at our customer base and helps customers realize the benefits of an integrated IDEXX diagnostic suite within their clinics. These multiplied effects supported the strong 15% global growth achieved in Catalyst placements in Q2, with strong gains globally in new and competitive accounts. ProCyte One also helps to advance our long-term growth strategy in international regions, where most veterinarians are trained to do hematology testing when assessing a patient's baseline health. Strong second quarter performance included double-digit CAG diagnostics recurring revenue growth, also benefited from the country-level commercial expansions we began in mid-2020. By increasing the density of our commercial reach, IDEXX sales professionals are better able to build relationships with veterinarians and communicate the benefits of diagnostics and software solution utilization, and how IDEXX can support them on that journey. The global opportunity we've identified is significant, and these expanded commercial teams are the tip of the spear in our multimodality strategy to drive continued sector development. Benefits from these investments are highly encouraged, as evidenced by strong installed base growth, supported by excellent placements in new and competitive accounts, revenue gains from new business, and improving customer engagement levels in key international regions. Of additional note, we have also executed a modest expansion of U.S. territories and customer-facing professionals based on highly attractive opportunities still before us in our largest geography. We anticipate all hiring to be completed and in place by the end of this year. In addition to high quality and quantity of instrument placements across regions in Q2, commercial execution helped drive continued adoption of IDEXX innovations, including within our rapid vector-borne disease screening franchise. Our VDC teams have done a great job communicating the health benefits of a full vector-borne disease screen versus heartworm-only testing. We see, consequently, 4Dx Plus making up a greater share of in-clinic vector-borne disease revenue. This adoption is supported by our growing installed base of SNAP Pros, which provides an integrated solution while managing workflow and ensuring charge capture. These focused commercial efforts, combined with relevant and easy-to-use products, highlights how we continue to build our customer base, which positions IDEXX well for long-term growth. Building on these commercial efforts, IDEXX's growth will continue to benefit from advancement of our innovation strategy, a core component of which is expanding our highly accurate and relevant test menu. We made a significant step forward in this area during the second quarter, when we announced the launch of the IDEXX Cystatin B test in our North American Reference Lab network. This novel marker leverages IDEXX IP to help clinicians detect kidney injury, a hard-to-diagnose condition that comprises approximately one-third of all kidney cases seen by veterinarians. Renal care is a critical area for diagnostics insights, since the kidneys regulate blood pressure, electrolyte balance, and red blood cell production, while also removing toxins. By adding Cystatin B to our renal portfolio, and by pairing it with IDEXX SDMA, our customers will have access to the most comprehensive view of kidney health, helping them uncover structural injury and impaired kidney function. What's even more exciting is we will leverage our SDMA playbook to support adoption by including Cystatin B in test panels for approximately two million patients annually at no additional cost, helping clinicians realize the benefits of IDEXX's world-class diagnostics and deliver a higher standard of care to their patients. IDEXX diagnostic solutions, like the innovative Cystatin B test, when used in an integrated way with our software portfolio, can contextualize an individual patient's health status and support the veterinarian with interpretation and drawing out the appropriate clinical insights. Our software portfolio, which includes a full stack of solutions, many of which leverage cloud technology, touches all areas of the veterinary clinic. From enabling patient check-ins and the full diagnostics workflow to pet owner communication and charge capture, IDEXX software solutions create a connected ecosystem that supports greater diagnostics utilization, while also helping our busy customers be more efficient. A key driver of customer interest we see in our software solutions is driven by the high demand customers are seeing for medical services. These solutions appeal to both independent and especially corporate customers, who are increasingly focused on using software to standardize their workflow at scale. Given this backdrop of high demand for pet healthcare services, busy clinics continue to appreciate the value of cloud-based products, as these intuitive and easy-to-administer products allow them to spend more time focusing on the patients that walk in the door, rather than on time-consuming back-office tasks. In IDEXX cloud data products, including our ezyVet and IDEXX Neo PIMS and IDEXX Web PACS imaging software, continue to be in high demand as a response to this trend. For example, second quarter cloud-based PIMS once again comprised over 90% of total PIMS placements, and as a result, make up nearly 50% of our PIMS installed base. This is a trend we expect to continue and are well positioned to address. In our digital imaging business, record first-half instrument placements supported double-digit organic growth and demonstrate that customers are increasingly choosing IDEXX to partner on this piece of their business, and helps grow our base for future high-margin recurring revenues. One driver of this interest is continued innovation of our IDEXX Web PACS software, which makes it even easier for clinicians to interpret and identify hard-to-detect internal abnormalities. The result of these efforts is an excellent customer experience, which helped earn a world-class NPS rating for our diagnostic imaging business. One proof point that the solid overall experience that customers of all types have with IDEXX. This concludes our review of our second quarter results. I would like to extend my thanks to the nearly 11,000 IDEXX employees who helped deliver continued strong performance, aligned with our purpose of enhancing the health and well-being of pets, people, and livestock. We look forward to building on this progress. Before we move to Q&A, I would like to remind you that we'll be hosting our annual Investor Day in August, beginning with the management dinner on Wednesday, August 9th, followed by presentations at our global headquarters in Westbrook, Maine, on Thursday, August 10th, at 8:00 A.M. Thursday's event will also be live-streamed and recorded via idexx.com for those who cannot make it in person. This is an exciting opportunity for the IDEXX leadership team to provide updates on our strategy, execution drivers, innovation cycle, and long-term growth potential. Participating will be members of my senior management team, including Dr. Tina Hunt, Executive Vice President, Strategy, Sector Development, and Global Operations, Dr. Mike Erickson, Senior Vice President and General Manager, Point of Care Diagnostics, Mike Lane, Executive Vice President and General Manager for Reference Laboratories and Information Technology, Michael Schreck, Senior Vice President and General Manager, Veterinary Software and Services and Corporate Accounts, and Brian McKeon, Executive Vice President and Chief Financial Officer. We're also excited to host a live customer conversation led by Jim Polewaczyk, Executive Vice President and Chief Commercial Officer, to provide a firsthand view of the role of diagnostics within the clinic and how IDEXX is supporting our customers in adapting to the dynamic sector backdrop. The event will last approximately four hours and will conclude with a Q&A session. With that, we'll end the prepared section of the call and open the line for Q&A. Thank you. If you would like to ask a question, please signal by pressing star one on your telephone keypad. If you are using a speakerphone, please make sure that your mute function is turned off to allow your signal to reach our equipment. Please limit yourself to one question and one follow-up question. Again, you may press star one to ask a question. We'll pause for just a moment to allow everyone an opportunity to signal. We'll take our first question from Nathan Rich with Goldman Sachs. Please go ahead. Great. Good morning. Thanks for the questions. Two questions on volumes, I guess first in, in the U.S.. Could you maybe talk, Brian, about how clinical visits trended over the course of the quarter? I know you kind of said they had softened earlier in the quarter. Just curious how the quarter played out relative to your expectations and, and kind of what you're looking for to see that flattening over the balance of the year. Then on international, what drove the improvement in the international CAG growth this quarter? I think kind of despite the improvement, reference lab kind of remains soft. You know, why do you think you maybe haven't seen more improvement in, in reference lab volumes? You know, can you maybe talk about expectations there for the back half of the year? Thank you. Thanks for your questions, Nate. On the first question, we saw a post-January, relatively similar clinical visit trends in the data. I think, with hindsight, January benefited from the year-on-year COVID lapping, and overall for the first quarter, it was flat, but that benefited from that dynamic. I think the clinical visit trends through Q2 were largely consistent. This was consistent with our expectation. We thought we'd see a reduction in the headwinds from the clinical visit capacity pullback that happened last year, and that we're still working through some compares on that front in the first half. That, that informed how we were thinking about the second half, that, you know, we, we would see that normalize and, and hopefully over time, improve given the, the, the strong underlying demand that we believe is out there. That's sort of the U.S. story. Let, let me give some context on international. I'm sure Jay can add to this, but the, the strength in international came from our in-clinic business, just the very strong growth in our instrument placements, customer engagement, supported strong consumable gains, and so I think that's directly related to our, our executional focus. As you pointed out, labs were relatively consistent. We're still seeing the, have seen the, the, the macro headwinds, relatively more in international markets. That's been a consistent story. That, that moderated what were double-digit growth rate benefits from the executional drivers that enabled us to get to, to double-digit overall growth in international markets. Just to add to that, Nate, you know, from a higher-level standpoint, the clinic economics and, you know, overall health of the clinics, you know, really is healthy. I think revenue, we, we showed that revenue is growing nicely, so certainly not a demand dynamic. As Brian said, you know, internationally, we've been benefiting really over, you know, a number of quarters of record placements. ProCyte One obviously fits well and leverages and multiplies the impact we've been able to have on total in-clinic placements. I think very strong execution. We're now seeing the benefits of the consumables growth, and, you know, that has a small ramp to it, but I think the business is healthy, and we saw positive volume growth in Q2 internationally. You know, I think, you know, the clinics are working through the, the type of capacity constraints and, and labor challenges that they've had earlier. You know, we expect that to continue over time. Great. Thanks for the details. We'll move to our next question from Chris Schott with J.P. Morgan. Your line is now open. Please go ahead. Hi, this is Ekaterina from J.P. Morgan on for Chris. Thank you so much for taking our questions. First, just on pricing. I know you probably can't give too much specifics, but directionally, any initial thoughts on how you're going to approach price increases in 2024? You know, on one hand, obviously inflation has slowed, but then, you also probably could see some upward pressure on costs. Does that warrant larger prices? Just how are you thinking about 2024 price increases? Then the second question is: if you think about both clinical visit growth and then utilization, any major differences between what you're seeing for your corporate clinic accounts versus your non-corporate, but owned, privately owned accounts? Thank you so much. Yeah. Good morning. Thanks, thanks for your question. On, on the pricing front, first, I just wanna reinforce, we have a consistent outlook for the second half of 2023 for 6%-7% overall net price improvement related to CAG Diagnostic recurring revenues. We're not prepared to share our plans for 2024. What I would note is that we'll have, as we've had in the past, a very thoughtful approach that's aligned with long-term sector development and the value that we deliver through our solutions and our innovations, and we'll evaluate and incorporate inflationary dynamics as part of that approach as we get closer to next year. Yeah, just a couple words, you know, about pricing. To Brian's point, we from a philosophical standpoint, we wanna make sure we continue to deliver really strong value. You know, we think that our pricing reflects the fact that we continue to do that. We see really very high retention levels in our business. We see an increase in adoption and utilization. So from the standpoint of, you know, I think customer receptivity, we think our pricing is appropriate given the circumstances. If you think about the, our latest, menu release in reference labs, it's that and B. It's a great example of how we add value, that we're increasing the menu. two million patients on a global basis, annual global basis, are gonna benefit from this. We're not increasing the, the price of our, of those, of those panels. I think it's just a great example of how, you know, we try to keep, you know, that, that value equation appropriately aligned to, you know, what our, what our customers need. In terms of corporate versus, you know, independent practices, a couple dynamics to keep in mind. You know, largely, we don't see big differences. Obviously, there, there's differences in things like the size of the practice. Corporate practices tend to be a bit larger. They're more specialty practices owned by corporates. They're focused, I think, increasingly on growth. We've seen nice interest, not just in our solutions, like in-clinic premium analyzers, but also software solutions, as they really try to operate the businesses in a more standardized way. You know, they're interested in the same type of diagnostic solutions that independent practices are. We, we see a lot of interest in things like preventive care, for example, 'cause it's a, it's a great way of, I think, continuing to engage, pet owners and, and clients, really uncover, I think, disease that may be otherwise subclinical or, or hidden, that drives the medical services envelope. Very similar profiles be-between the two, with some, you know, small differences that I just mentioned. Thank you so much. We'll move to our next question from Michael Ryskin with Bank of America. The floor is yours. Great, thanks for taking the question. Two quick ones from me. First, could you expand a little bit on what you saw in the quarter, between wellness, and clinical, and especially as it touches on preventative care in the United States? Just wondering if you're starting to see, or if you are seeing any, any separation there, just given the price increases, you know, between last year and this year, and just thinking about, you know, willingness to spend, consumer sensitivity, if you're seeing any impact on demand from those side of things. Then I have a follow-up. Yeah, good. Yeah, good, good morning, Mike. You know, it's not unusual to see some variability in a given quarter between wellness and, let's say, non-wellness or sick patient visits. When you take a look at Q2, on a two-year basis, they were very similar growth profile, profiles between the two. It's, you know, small things that can, you know, account for some variability, whether, you know, more people are traveling, weather, what have you. You know, what we tend to look at is we tend to look at those diagnostic parameters or menu that are used in wellness areas like 4Dx Plus, you know, for example, and that was very, you know, strong growth. We really haven't seen any drop-off. Okay. All right. Thanks. That's helpful. Then, this is a little bit of looking ahead to 3Q, just focusing specifically on international and Europe in particular. I know in prior years, you guys have seen occasionally a little bit of a headwind from weather, from extreme weather events, whether it's heat waves or hurricanes, et cetera, just because it would impact pet owner behavior or ability or willingness to visit clinics, things like that. Just thinking about the heat wave in Europe that's been, you know, going on for the last month or so. Is that factored into your guidance at all? Are you anticipating a little bit of an impact on revenues? I know you called out a day's impact. I'm wondering if, if there's any other wiggle room built in there, for, you know, just the extreme weather? Thanks. Yeah, Mike, you know, I think weather at times can have impact on the business. Our, our outlook that I mentioned, was that of, for Q3 was organic revenue growth at the lower end of our full year, outlook range, and that, that basically aligns with consistent, strong execution trends and adjustments for the, the days effects and just, obviously, our pricing's evolving a bit here as well. Just compared to H1. It's, it's targeting consistent, strong execution and, you know, we'll, we'll, we'll address those types of impacts if they occur in, in the business, as, you know, and, and report on that, if that, if that turns out to be a factor. All right. Thanks. If you find that your question has been answered, you may remove yourself from the queue by pressing star two. Once again, if you would like to join the queue, you may press star one on your telephone keypad at this time. We'll take our next question from Ryan Daniels with William Blair. Please go ahead. Yeah, good morning. Thanks for taking the questions. Just wanted to dive into the expansion of the U.S. customer-facing organization a little bit more. I know it's been a while, and you've been more focused on OUS expansion. Can you talk a little bit about, you know, strategically, what drove that? Is it just new clinic openings? Are you seeing more opportunities to visit vets? Is it kind of a competitive opening? Just any color there would be helpful. Sure. We- you know, we've grown significantly in the U.S. over the last, you know, years. I think it's a bit over three years since we did a last expansion. We're very optimistic about the long-term growth prospects of the U.S.. It's our largest market. You know, it's something that we really evaluate on an ongoing basis. We want to make sure that we have the right account coverage, and we're be able to- we're able to support, you know, product and innovation priorities over time. We felt that it made sense. Really, it just comes down to that. Okay, great. Then it's been a while since you've talked about a new big corporate win, and I'm curious if you could talk about maybe the competitive environment more broadly, post some M&A activity in your space. Are you seeing that open up any opportunities or just normal course of business or, or more innovation? Thanks. Yeah, I mean, I think the, it's really normal course of business. We do very well with corporates. You know, we occasionally talk about it, but, you know, from a corporate account standpoint, I think they, increasingly see the integrated benefits of multimodality solution and software. They're focused on workflow, and they're focused on productivity, given the capacity constraints and the need to really operate these models. I think from a solution standpoint, they appreciate what we're able to bring. We have a footprint that's obviously very broad and deep and can partner with them wherever they are. I think that it's a very natural fit from that standpoint. Great. Thank you so- We'll move to our next question from Jon Block with Stifel. Please go ahead. Thanks, guys, and good morning. I'll break up my questions. Brian, it seems like the visits are expected to get a bit better in the second half of 2023. I think if I had it right, you mentioned flattish, give or take, year-over-year, but, you know, 2Q 2023 was down from the 1Q 2023 level. Maybe if you can elaborate a little bit on what helps the 2H 2023 visits from those first half levels. We did some work around labor constraints that might be easing a bit, but would love your thoughts on the improvement in 2H 2023. Do we think about that trend line arguably continuing into 2024? I'll ask my follow-up. Thanks, Jon, for your question. I, I think the a part of it is working through this effect we saw in 2022, where there was a pullback in capacity. So I think that pullback was largely happening in the first half of 2022, and so we knew we'd still be working through some of that, and I think that there'll be some relative improvement, of which I think you were pointing out. I think overall, we, we, you know, anticipate that we continue to look at the, the growth and demand that we see in terms of the expansion of the pet population and increased interest in, in pet healthcare, that being affirmed in a lot of the qualitative work that we do. Believe that there's underserved demand and believe that, you know, that, that will be a positive tailwind over the long term. Continue to feel that's very much part of the, the growth build that we have for the long term. You know, we're working through some dynamics here to help clinics adapt to that and improve their productivity, and I, I think we can be helpful. That- I think our long-term optimism is intact. That should be a positive driver over time, and we're, you know, we've made some positive transitions here during the first part of this year. I'd, I'd, I'd also highlight, you know, we- sometimes we, we spend a lot of time on the U.S. trends that the... You know, internationally, we've seen relatively more, kind of the same story, how headwind effect that we've been able to offset with our benefits from our business expansion and engagement and innovations that we're bringing in. I think internationally, we see the same kind of a story, that over time, there's very strong demand for pet healthcare, and it's probably relatively greater macro impacts in the near term, but we think that over time, that will improve as well. Got it. That was very helpful. Thanks for that. Maybe just to pivot to innovation. You know, when I look back to SediVue Dx, I believe there was a staggered launch with the U.S. leading and then international following. Any color on how we think of those pending new systems? Will we see sort of the same approach play out, you know, the staggered call it? Then I, I don't know if you've talked about this before, but will the manufacturing be handled by yourself or your partners on those new systems? Just, sorry, a quick clarifying question. Brian, I think price in the quarter, if I got you right, was closer to 9% for 2Q, but is full year 2023 price still expected to be between 7%-8%? Thanks, guys. Well, I'll let Jay dive into the platforms. On your latter question, yes, that's correct. Dude, that's what we said. From a platform standpoint, I'm obviously not gonna talk about it until we talk about it and get closer, you know, to the launch. What I will say, Jon, from a premium instrument placement and how we think about the opportunity, the, you know, the we typically, you know, do start with the U.S. market, but there's nothing that says, you know, we have to do that. The key is really to build an installed base and get that consumable revenue stream, you know, moving. That takes time. I think SediVue Dx was one example, and, you know, we launched it, what, 7+ years ago, and we built the installed base, and we have a nice profile. We, we really focus on, on being able to really drive sector, development and adoption and solve those clinical problems, and everything else takes care of itself from there. Thanks, guys. Thank you. Our next question comes from David Westenberg with Piper Sandler. Please go ahead. Hi, thank you for taking the questions, and congrats on continued strong execution here. Just a quick question, again, on that theme of pricing. I know that's a, one what a lot of people talk about, but maybe more on the clinic level. As we see continued constraints in, in labor, and that's really what we're seeing, are you seeing pressure of your-- from your customers to raise prices themselves? Do you think that's gonna continue for, say, maybe the next six months or so? Do you see any, any kind of, you know, potential to maybe e-ease in volume as their prices go up? You know, is it hit equilibrium as because, you know, maybe labor is used in, in a more optimal way? Just a second, two really clarifying short questions. Can you just say how many territories you actually added? Just on the gross margin commentary, you said, Was it $18 million in terms of what the contribution or was because of hedge gains? I'm just trying to make a sense of the 100 basis points of gross margin expansion. Thank you. That's a quite a number of questions today. Let me, you know, let me just start with the, the pricing piece. Obviously, clinics control that. If you, if you go back, you know, the last five or six quarters, you know, a lot of clinics took multiple price increases on an annual basis. They, they typically, you know, if, if you go pre-pandemic or, or pre-inflationary times, they would increase their prices, you know, one time per year. I think a number of clinics, on average, increase at least two, in some cases, three, and, and that was really just to reflect the higher costs of labor and, and so retaining staff, and in some cases, they needed to add to staff. So from an employment level standpoint, you know, we think clinics have... are catching up or have caught up. They've, they've hired people. That's not to say they're all working, you know, 40-hour weeks. You know, in terms of pricing going forward, I think that's really just a reflection of what happens, you know, in the economy. You know, at this point, it appears that inflation, you know, has moderated, you know, somewhat, but we'll have to see how that plays out, and I think they'll make decisions based on how their businesses are doing. You know, right now, I think, clinic revenue, practice revenue is pretty healthy, you know, for approaching, you know, 6% or so. I think they, they feel like they're in a pretty good place from an economic standpoint. Dave, to your questions on gross margin and hedge gains, what we were trying to highlight is in terms of our year-over-year performance on margins, that there is an effect from in 2022 as the dollar was strengthening. We, we, we hedge out, we tend to hedge in advance of the year to help us with our planning. We had in the second half of last year, we recognized the benefit from $18 million in hedge gains. What, what's happened with the foreign exchange dynamics is they've actually moved into a positive zone, you know, so we have some benefit on revenue, but we're gonna have some reported year-on-year foreign exchange headwinds. We estimated 70, 80 basis points in H2 that relate to just lapping those hedge gains that'll roll off eventually. Just trying to highlight that as a factor. We, we try to each quarter, note what those gains or losses are, so you have that, and that, that's in our disclosures as well. But just wanted to highlight that as your to understand kind of the outlook. Thank you for taking my long questions. Our last question comes from Balaji Prasad with Barclays. Please go ahead. Hi, this is Micaela on for Balaji. Thanks for taking our questions. Can you talk about anything particular you saw in the quarter that drove the two-year stacked growth deceleration in CAG recurring? Thank you so much. What's that question? Was the question anything that drove the two-year stack CAG Diagnostics recurring revenue growth? Yeah. Okay. Yeah, I mean, the, as we had a very strong quarter in terms of CAG Diagnostics recurring revenue as indicated. Yes, It was really in part driven by pricing as well as, you know, volume growth and just really good execution. Retention of customers was very good. We saw adoption and utilization of diagnostics really across our broad spectrum. Obviously, consumables in our in-clinic business was very, very strong, and we saw nice performance in international. That's really more of a cumulative impact of placements that we've, you know, I think, achieved over the last, you know, four-six quarters. Yeah, I'd highlight the two-year. I'm just looking at the numbers. On a two-year basis, we have relatively consistent performance, Q1 and Q2, so I think we had similar trends, similar benefits, and as Jay highlighted, I think we've had very good execution, including some benefits from the higher pricing this year. Okay, with that, we'll conclude the Q&A portion of the call this morning. Thanks for everyone on the phone for your participation this morning. It's an honor to share another quarter of solid financial and strategic results as we continue to address the significant long-term opportunity to enhance standards of care for companion animals through our unwavering focus on diagnostic insights. With that, we'll conclude the call. Hope to see you all at Investor Day, and thank you.